Validation of a New Device to Measure Neuromuscular Disease Progression

Brief Summary

Official Title: “Validation of a New Device to Measure Neuromuscular Disease Progression”

There is a great need for the development of sensitive outcomes that allow experimental drugs to be tested in human subjects more efficiently. If we could more precisely measure whether an experimental drug slows the progression of ALS or other neuromuscular diseases, this would allow more drugs to be tested quicker and at less expense. We have developed a new device that accurately measures isometric strength called: Accurate Test of Limb Isometric Strength (ATLIS). This device was designed to be portable, quick, and easy to use, while generating accurate and reliable, interval level data. This study will enable us to test the reliability and validity of ATLIS.

  • Study Type: Observational
  • Study Design: Observational Model: Case Control, Time Perspective: Cross-Sectional
  • Study Primary Completion Date: September 2010

Arms, Groups and Cohorts in this Clinical Trial

  • 1
    • Individuals with ALS
  • 2
    • Healthy Adults

Outcome Measures for this Clinical Trial

Primary Measures

  • isometric strength measures
    • Time Frame: cross sectional
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • All subjects must be at least 18 years old and able to provide informed consent
  • All subjects have no health conditions that limit their ability to safely exert maximal force using the muscles in their arms and legs.
  • Subjects with a diagnosis of laboratory supported probable, probable or definite ALS according to the World Federation of Neurology El Escorial, as determined by their referring neurologist at MGH.
  • All subjects must be able to speak and understand English.

Exclusion Criteria

  • Presence of significant arthritis, orthopedic conditions, or cardio-pulmonary conditions or other medical conditions that may limit the ability to maximally exert force safely.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • Massachusetts General Hospital
  • Provider of Information About this Clinical Study
    • Patricia L. Andres, Massachusetts General Hospital
  • Overall Official(s)
    • Patricia L. Andres, MS, DPT, Principal Investigator, Mass. General Hospital


Clinical Trials content is provided directly by the US National Institutes of Health via and is not reviewed separately by Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: